Trust in the FDA is eroding: Transparency in food and drugs is imperative
How scientific integrity and predictability can restore the FDA's credibility
1FDA's unique role
The FDA sits at the critical intersection of science, medicine, and public health. Patients rely on therapy evaluations, innovators need predictable pathways, and investors trust evidence-based decisions. But recent inconsistencies have shaken this trust.
2Impact of eroding trust
From rare disease therapies to Moderna's mRNA vaccine, FDA's abrupt policy shifts have impacted entire innovation ecosystems. Companies now complain about unpredictable decision-making processes that create business uncertainty.
3Scientific integrity questioned
FDA's deviation from evidence-based decision-making in recent years has alarmed the scientific community. Rare disease advocates emphasize that consistency is vital when patients have no alternative treatment options.
4The Replimune case
Replimune's metastatic melanoma treatment highlights FDA's alleged shifting evidence expectations. Similar issues emerged with Huntington's disease and Hunter syndrome therapies. These cases raise questions about consistent standard application.
5Real-world evidence gap
Critics argue FDA undervalues real-world evidence and expert input, particularly crucial for rare diseases where clinical trial data is limited. This oversight creates approval bottlenecks for life-saving treatments.
6Cost of regulatory uncertainty
FDA's delayed or reversed decisions jeopardize pharma companies' multi-year research and million-dollar investments. This uncertainty slows innovation and ultimately delays patient access to critical therapies.
7Steps toward recovery
Under interim leadership, FDA is revisiting controversial decisions. This review process aims to increase transparency and clarify scientific rationale. However, lasting change requires institutional reforms beyond temporary fixes.
8Pasteur's legacy
As Louis Pasteur noted, science is the highest expression of a nation. Restoring trust in FDA matters not just for US biomedical leadership, but for global patient access to life-saving treatments developed through rigorous science.
Original article: Fortune | FORTUNE — FDA'ya olan güven eriyor: Gıda ve ilaçlarda şeffaflık şart